Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 4/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381208 | 0.96 | KMT2A (0.39) | ALDH1A1KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL6381151 | 0.84 | HPGD (0.38) | ALDH1A1KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL6381885 | 0.73 | HTT (0.39) | ALDH1A1KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL6427012 | 0.73 | ALDH1A1 (0.34) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15567088 | 0.72 | MAPT (0.38) | ALDH1A1KMT2AMEN1HPGDLMNA | |
| SCHEMBL6382528 | 0.71 | ALDH1A1 (0.34) | ALDH1A1KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL6384570 | 0.70 | ALDH1A1 (0.36) | ALDH1A1HPGDSMN1; SMN2MAPTHTT | |
| SCHEMBL6386074 | 0.69 | GAA (0.34) | — | |
| SCHEMBL6385540 | 0.65 | GFER (0.34) | — | |
| SCHEMBL5273884 | 0.62 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107412-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107412-A1 | Pharmaceutically active compounds | PDE5A, PDE2A, PDE3B | ALDH1A1 720/4885KMT2A 4385/4885MEN1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.